Exploring GLP-1 Drugs for Alzheimer’s Prevention

Glucagon-like peptide-1 (GLP-1) drugs have surged in popularity due to their effect on the digestive system, helping patients manage Type 2 diabetes, weight and cardiovascular risk. But preclinical studies have found these drugs may also have an effect on the brain. Funded by a two-year, nearly $350,000 grant from the National Institutes of Health’s National Institute on Aging, the University of Cincinnati’s Shawn Xiong, PhD, is analyzing real-world patient data to learn more about how GLP-1 drugs affect people with mild cognitive impairment, a common precursor to Alzheimer’s disease.